AnaptysBio Reports Jemperli Sales Up 29%
The San Diego biotech posted fiscal first-quarter 2027 results, with net income from continuing operations of $3.9 million.
Updated on Nov. 12, 2026 in Corporate Finance

AnaptysBio reported fiscal first quarter 2027 financial results for the quarter ended September 30, 2026, showing net income from continuing operations of $3.9 million, or $0.13 per share. Jemperli global net sales reached $1.0 billion for the nine months ended September 30, 2026, up 29% year over year.
Why it matters
The results reflect growth in Jemperli, the company's immunotherapy approved in the U.S. for stage II and III MSI-H/dMMR locally advanced rectal cancer. The company's cash position and pending litigation with GSK and Tesaro remain central to its financial outlook.
The company reported $153.0 million in cash, cash equivalents and investments as of September 30, 2026, down $11.1 million from June 30, 2026, and collaboration revenue of $30.3 million compared with $76.3 million a year earlier. The post-trial outcome in the GSK and Tesaro case is still pending.
The players
AnaptysBio
AnaptysBio is a San Diego-based biotechnology company that develops antibody-based therapies and receives royalties from Jemperli.
GSK
GSK is a British multinational pharmaceutical company and a party to ongoing litigation with AnaptysBio.
Tesaro
Tesaro is a pharmaceutical company, now part of GSK, that is a party to litigation with AnaptysBio.
The details
Collaboration revenue declined primarily because the same period in 2025 included $50 million in milestone revenue. General and administrative expenses from continuing operations were $11.6 million, driven largely by legal costs tied to the GSK and Tesaro lawsuit, along with audit, tax and cost-allocation expenses. Jemperli royalties rose 11% quarter over quarter.
Timeline
April 20, 2026: AnaptysBio completed its separation from First Tracks Biotherapeutics.
October 20, 2026: A post-trial hearing was held before the Delaware Chancery Court in the GSK and Tesaro litigation.
December 12, 2026: FDA target action date for Quimilza in GPP.
Corporate Finance Context
Following its April 2026 separation from First Tracks Biotherapeutics, AnaptysBio now reports results with First Tracks reclassified as discontinued operations beginning in Q2 2026. The company expects Jemperli royalties to exceed $390 million annualized as early as 2029.
Investors tracking AnaptysBio should weigh the pending GSK and Tesaro judgment, which could affect legal costs and the company's outlook. The company's projected Jemperli royalty stream is a central factor in its long-term financial profile.
The takeaway
AnaptysBio's near-term financial picture depends heavily on Jemperli royalty growth and the outcome of its litigation with GSK and Tesaro. Investors should track both the forthcoming judgment and the company's debt paydown timeline.
What happens next
A judgment in the GSK and Tesaro litigation is anticipated in calendar Q4 2026 or Q1 2027, and the remaining approximately $270 million non-recourse debt monetization is expected to be paid down in calendar H2 2027.
Further reading
Explore more Corporate Finance coverage for context on how biotech companies manage royalties, debt and litigation.
Source note: This article includes information reported by The Manila times.










